Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Rao Tekmal R, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR. Liu J, et al. Among authors: viswanadhapalli s. Oncotarget. 2017 Jul 25;8(30):50002-50014. doi: 10.18632/oncotarget.18442. Oncotarget. 2017. PMID: 28654894 Free PMC article.
Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.
Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK. Raj GV, et al. Among authors: viswanadhapalli s. Elife. 2017 Aug 8;6:e26857. doi: 10.7554/eLife.26857. Elife. 2017. PMID: 28786813 Free PMC article.
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK. Viswanadhapalli S, et al. Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29. Mol Cancer Ther. 2019. PMID: 31142661 Free PMC article.
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S, Ma S, Sareddy GR, Lee TK, Li M, Gilbreath C, Liu X, Luo Y, Pratap UP, Zhou M, Blatt EB, Kassees K, Arteaga C, Alluri P, Rao M, Weintraub ST, Tekmal RR, Ahn JM, Raj GV, Vadlamudi RK. Viswanadhapalli S, et al. Breast Cancer Res. 2019 Dec 26;21(1):150. doi: 10.1186/s13058-019-1227-8. Breast Cancer Res. 2019. PMID: 31878959 Free PMC article.
EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling.
Yue X, Wu F, Wang J, Kim K, Santhamma B, Dileep KV, Zhang KYJ, Viswanadhapalli S, Vadlamudi RK, Ahmed G, Feng Z, Nickisch K, Hu W. Yue X, et al. Among authors: viswanadhapalli s. J Mol Cell Biol. 2020 Jul 3;12(6):477-480. doi: 10.1093/jmcb/mjaa008. J Mol Cell Biol. 2020. PMID: 32221559 Free PMC article. No abstract available.
44 results